Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Palisade Bio Inc (PALI)

Palisade Bio Inc (PALI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,251
  • Shares Outstanding, K 936
  • Annual Sales, $ 250 K
  • Annual Income, $ -12,300 K
  • 60-Month Beta 1.36
  • Price/Sales 16.86
  • Price/Cash Flow N/A
  • Price/Book 0.38
Trade PALI with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -7.95
  • Growth Rate Est. (year over year) +12,666.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.29 +5.83%
on 06/04/24
5.15 -11.84%
on 06/20/24
-0.28 (-5.81%)
since 05/31/24
3-Month
3.82 +18.85%
on 04/12/24
9.65 -52.95%
on 04/16/24
-1.20 (-20.85%)
since 04/02/24
52-Week
3.82 +18.85%
on 04/12/24
36.60 -87.60%
on 07/26/23
-20.96 (-82.20%)
since 06/30/23

Most Recent Stories

More News
JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023

- Live video webcast interactive Q&A with participating companies -

EVFM : 0.0095 (+5.56%)
GRI : 1.6400 (-13.68%)
MBRX : 3.57 (+3.48%)
XBIO : 4.10 (-1.68%)
AREC : 0.7130 (-4.23%)
CNSP : 1.2600 (-11.27%)
NVNO : 5.07 (-0.98%)
PALI : 4.54 (+5.58%)
Palisade Bio (NASDAQ: PALI) Awarded Fast Track Designation from U.S. FDA for LB1148

Palisade Bio, Inc. (NASDAQ: PALI) is engaged as a biopharmaceutical company, which is focused on the research and development of

PALI : 4.54 (+5.58%)
Palisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that Protect Intestinal Barrier Health

New website aligns with company’s mission to become a global leader in addressing diseases linked to intestinal barrier disruption and establishing new...

PALI : 4.54 (+5.58%)
Palisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

CARLSBAD, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for...

PALI : 4.54 (+5.58%)
Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function

Completion of enrollment for Phase 3 study targeted within 18-24 months In multiple clinical studies, LB1148 has demonstrated statistically significant...

PALI : 4.54 (+5.58%)
Palisade Bio to Present at the 2022 BIO International Convention

In-person presentation on Monday, June 13th at 1:45 PM PT...

PALI : 4.54 (+5.58%)
Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022 Ongoing Phase 2 study of LB1148 for...

PALI : 4.54 (+5.58%)
Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires

CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute...

PALI : 4.54 (+5.58%)
Palisade Bio Announces $2.0 Million Registered Direct Offering

CARLSBAD, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company” or “Palisade Bio”), a clinical-stage...

PALI : 4.54 (+5.58%)
Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery

NMPA clearance expands global Phase 3 clinical development program; Company recently announced clearance from U.S. Food and Drug Administration to commence...

PALI : 4.54 (+5.58%)

Business Summary

Palisade Bio Inc. is a late-stage biopharma company advancing therapies which help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio Inc., formerly known as Seneca Biopharma Inc., is based in CARLSBAD, Calif.

See More

Key Turning Points

3rd Resistance Point 4.91
2nd Resistance Point 4.74
1st Resistance Point 4.64
Last Price 4.54
1st Support Level 4.37
2nd Support Level 4.20
3rd Support Level 4.10

See More

52-Week High 36.60
Fibonacci 61.8% 24.08
Fibonacci 50% 20.21
Fibonacci 38.2% 16.34
Last Price 4.54
52-Week Low 3.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar